Read by QxMD icon Read


Bernard Iung, Victoria Delgado, Raphael Rosenhek, Susanna Price, Bernard Prendergast, Olaf Wendler, Michele De Bonis, Christophe Tribouilloy, Arturo Evangelista, Alexander Bogachev-Prokophiev, Astrid Apor, Hüseyin Ince, Cécile Laroche, Bogdan A Popescu, Luc Piérard, Michael Haude, Gerhard Hindricks, Frank Ruschitzka, Stephan Windecker, Jeroen J Bax, Aldo Maggioni, Alec Vahanian
Background: Valvular heart disease (VHD) is an important cause of mortality and morbidity and has been subject to important changes in management. The VHD II survey was designed by the EURObservational Research Programme of the European Society of Cardiology (ESC) to analyze actual management of VHD and compare practice with guidelines. Methods: Patients with severe native VHD or previous valvular intervention were enrolled prospectively across 28 countries over a 3-month period in 2017. Indications for intervention were considered concordant if the intervention was performed or scheduled in symptomatic patients, corresponding to Class I recommendations specified in the 2012 ESC and in the 2014 American Heart Association/American College of Cardiology VHD guidelines...
September 12, 2019: Circulation
John W Eikelboom, Stuart J Connolly, Jacqueline Bosch, Olga Shestakovska, Victor Aboyans, Marco Alings, Sonia S Anand, Alvaro Avezum, Scott D Berkowitz, Deepak L Bhatt, Nancy Cook Bruns, Camilo Felix, Keith A A Fox, Robert G Hart, Aldo P Maggioni, Paul Moayyedi, Martin O'Donnell, Lars Rydén, Peter Verhamme, Petr Widimsky, Jun Zhu, Salim Yusuf
Background: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer. Methods: We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, and determined the hazard of new cancer diagnosis after bleeding at these sites. Results: Of 27,395 patients enrolled (mean age 68, women 21%), 2,678 (9...
September 12, 2019: Circulation
Senthil Selvaraj, Brian Claggett, Andrea Pozzi, John J V McMurray, Pardeep S Jhund, Milton Packer, Akshay S Desai, Eldrin F Lewis, Muthiah Vaduganathan, Martin P Lefkowitz, Jean L Rouleau, Victor C Shi, Michael R Zile, Karl Swedberg, Scott D Solomon
Background: The contemporary prognostic value of the physical examination, beyond traditional risk factors including natriuretic peptides (NPs), risk scores, and symptoms, in heart failure with reduced ejection fraction (HFrEF) is unknown. We sought to determine the association between physical signs of congestion at baseline and during study follow up with quality of life (QoL) and clinical outcomes and to assess the treatment effects of sacubitril/valsartan on congestion. Methods: We analyzed participants from PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) with an available physical examination at baseline...
September 12, 2019: Circulation
Derek P Chew, Kristina Lambrakis, Andrew Blyth, Anil Seshadri, Michael J R Edmonds, Tom Briffa, Louise A Cullen, Stephen Quinn, Jonathan Karnon, Anthony Chuang, Adam J Nelson, Deborah Wright, Matthew Horsfall, Erin Morton, John K French, Cynthia Papendick
BACKGROUND: High-sensitivity troponin assays promise earlier discrimination of myocardial infarction (MI). Yet, the benefits and harms of this improved discriminatory performance when incorporated within rapid testing protocols, with respect to subsequent testing and clinical events, has not been evaluated in an in-practice patient-level randomized study. This multi-center study evaluated the non-inferiority of a 0/1-hour high-sensitivity troponin T (hs-cTnT) protocol compared with a 0/3-hour masked hs-cTnT protocol in suspected ACS patients presenting to the emergency department (ED)...
September 3, 2019: Circulation
Sana M Al-Khatib, Fred M Kusumoto
No abstract text is available yet for this article.
September 3, 2019: Circulation
Lars Søndergaard, Jeffrey J Popma, Michael J Reardon, Nicolas M Van Mieghem, G Michael Deeb, Susheel Kodali, Isaac George, Mathew R Williams, Steven J Yakubov, Arie P Kappetein, Patrick W Serruys, Eberhard Grube, Molly B Schiltgen, Yanping Chang, Thomas Engstrøm
BACKGROUND: For patients with severe aortic stenosis (AS) and coronary artery disease (CAD), the completely percutaneous approach to aortic valve replacement and revascularization has not been compared to the standard surgical approach. METHODS: The prospective SURTAVI trial enrolled intermediate-risk patients with severe AS from 87 centers in the United States, Canada, and Europe between June 2012 and June 2016. Complex coronary artery disease with SYNTAX score >22 was an exclusion criterion...
September 3, 2019: Circulation
Benedikt Schrage, Alicia Uijl, Lina Benson, Dirk Westermann, Marcus Ståhlberg, Davide Stolfo, Ulf Dahlström, Cecilia M Linde, Frieder Braunschweig, Gianluigi Savarese
BACKGROUND: Most randomized trials on implantable cardioverter-defibrillator (ICD) use for primary prevention of sudden cardiac death in heart failure with reduced ejection fraction (HFrEF) enrolled patients >20 years ago. We investigated the association between ICD use and all-cause mortality in a contemporary HFrEF cohort and examined relevant subgroups. METHODS: Patients from the Swedish HF Registry (SwedeHF) fulfilling the European Society of Cardiology criteria for primary prevention ICD were included...
September 3, 2019: Circulation
Matthew T Roe, Qian H Li, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Shaun G Goodman, Robert A Harrington, J Wouter Jukema, Patricio Lopez-Jaramillo, Renato D Lopes, Michael J Louie, Patrick M Moriarty, Michael Szarek, Robert Vogel, Harvey D White, Andreas M Zeiher, Marie T Baccara-Dinet, Ph Gabriel Steg, Gregory G Schwartz
No abstract text is available yet for this article.
September 2, 2019: Circulation
Anda Bularga, Kuan Ken Lee, Stacey Stewart, Amy V Ferry, Andrew R Chapman, Lucy Marshall, Fiona E Strachan, Anne Cruickshank, Donogh Maguire, Colin Berry, Iain Findlay, Anoop S V Shah, David E Newby, Nicholas L Mills, Atul Anand
BACKGROUND: Guidelines acknowledge the emerging role of high-sensitivity cardiac troponin for risk stratification and the early rule-out of myocardial infarction, but multiple thresholds have been described. We evaluate the safety and effectiveness of risk stratification thresholds in patients with suspected acute coronary syndrome. METHODS: Consecutive patients with suspected acute coronary syndrome (n=48,282) were enrolled in a multi-center trial across ten hospitals in Scotland...
September 1, 2019: Circulation
David D Berg, Stephen D Wiviott, Benjamin M Scirica, Yared Gurmu, Ofri Mosenzon, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Per Johanson, Peter A Johansson, Anna Maria Langkilde, Itamar Raz, Eugene Braunwald, Marc S Sabatine
No abstract text is available yet for this article.
August 31, 2019: Circulation
Jakob Lüker, Kathrin Kuhr, Arian Sultan, Georg Nölker, Hazem Omran, Stephan Willems, René Andrié, Jan W Schrickel, Stefan Winter, Dirk Vollmann, Roland R Tilz, Alexander Jobs, Christian-H Heeger, Andreas Metzner, Sven Meyer, Karl Mischke, Andreas Napp, Andreas Fahrig, Susanne Steinhauser, Johannes Brachmann, Stephan Baldus, Rajiv Mahajan, Prashanthan Sanders, Daniel Steven
BACKGROUND: Atrial arrhythmias are common in patients with implantable cardioverterdefibrillator (ICD). External shocks and internal cardioversion through commanded ICD shock for electrical cardioversion are used for rhythm-control. However, there is a paucity of data on efficacy of external versus internal cardioversion and on the risk of lead and device malfunction. We hypothesized that external cardioversion is non-inferior to internal cardioversion for safety and superior for successful restoration of sinus rhythm...
August 30, 2019: Circulation
Wen Tian, Xinguo Jiang, Yon K Sung, Eric Shuffle, Ting-Hsuan Wu, Peter N Kao, Allen B Tu, Peter Dorfmüller, Aiqin Cao, Lingli Wang, Gongyong Peng, Yesl Kim, Patrick Zhang, James Chappell, Shravani Pasupneti, Petra Dahms, Peter Maguire, Hassan Chaib, Roham Zamanian, Marc Peters-Golden, Michael P Snyder, Norbert F Voelkel, Marc Humbert, Marlene Rabinovitch, Mark R Nicolls
BACKGROUND: Bmpr2 mutations are critical risk factors for hereditary pulmonary arterial hypertension (hPAH) with approximately 20% of carriers developing disease. There is an unmet medical need to understand how environmental factors, such as inflammation, render Bmpr2 mutants susceptible to PAH. Overexpressing 5-lipoxygenase (5-LO) provokes lung inflammation and transient PAH in Bmpr2+/- mice. Accordingly, 5-LO and its metabolite, leukotriene B4 (LTB4 ), are candidates for the 'second hit'...
August 29, 2019: Circulation
Ashna Khanna, Priscila Pequeno, Sumit Gupta, Paaladinesh Thavendiranathan, Douglas S Lee, Husam Abdel-Qadir, Paul C Nathan
No abstract text is available yet for this article.
August 26, 2019: Circulation
Diane Treat-Jacobson, Mary M McDermott, Joshua A Beckman, Marsha A Burt, Mark A Creager, Jonathan K Ehrman, Andrew W Gardner, Ryan J Mays, Judith G Regensteiner, Dereck L Salisbury, Erica N Schorr, M Eileen Walsh
Patients with lower-extremity peripheral artery disease (PAD) have greater functional impairment, faster functional decline, increased rates of mobility loss, and poorer quality of life than people without PAD. Supervised exercise therapy (SET) improves walking ability, overall functional status, and health-related quality of life in patients with symptomatic PAD. In 2017, the Centers for Medicare & Medicaid Services released a National Coverage Determination (CAG-00449N) for SET programs for patients with symptomatic PAD...
August 26, 2019: Circulation
Niclas Svedberg, Johan Sundström, Stefan James, Ulf Hållmarker, Kristina Hambraeus, Kasper Andersen
No abstract text is available yet for this article.
August 26, 2019: Circulation
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett, Shaun G Goodman, Ronald M Goldenberg, Mohammed Al-Omran, Richard E Gilbert, Deepak L Bhatt, Lawrence A Leiter, Peter Jüni, Bernard Zinman, Kim A Connelly
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower cardiovascular events in type 2 diabetes (T2DM) but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with T2DM and coronary artery disease (CAD). METHODS: Between November 2016 and April 2018, we recruited 97 individuals ≥40 and ≤80 years old with glycated hemoglobin 6.5 to 10.0%, known CAD and estimated glomerular filtration rate (eGFR) ≥60mL/min/1...
August 22, 2019: Circulation
Yasuyoshi Ouchi, Jun Sasaki, Hidenori Arai, Koutaro Yokote, Kazumasa Harada, Yasuo Katayama, Takao Urabe, Yasufumi Uchida, Masaru Hayashi, Naoto Yokota, Hirokazu Nishida, Takatoshi Otonari, Tadashi Arai, Ichiro Sakuma, Kazuo Sakabe, Masayasu Yamamoto, Takashi Kobayashi, Shinichi Oikawa, Shizuya Yamashita, Hiromi Rakugi, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Masanari Kuwabara, Hideki Ito
BACKGROUND: Evidence regarding the primary prevention of coronary artery disease (CAD) events by LDL-C-lowering therapy in older individuals aged ≥75 years is insufficient. This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients. METHODS: This multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions in Japan examined the preventive efficacy of ezetimibe for patients aged ≥75 years with elevated LDL-C without history of coronary artery disease...
August 22, 2019: Circulation
Susanna C Larsson, Hugh S Markus
No abstract text is available yet for this article.
August 19, 2019: Circulation
Ann C Skulas-Ray, Peter W F Wilson, William S Harris, Eliot A Brinton, Penny M Kris-Etherton, Chesney K Richter, Terry A Jacobson, Mary B Engler, Michael Miller, Jennifer G Robinson, Conrad B Blum, Delfin Rodriguez-Leyva, Sarah D de Ferranti, Francine K Welty
Hypertriglyceridemia (triglycerides 200-499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 mg/dL) are far less frequently observed. Both are becoming increasingly prevalent in the United States and elsewhere, likely driven in large part by growing rates of obesity and diabetes mellitus. In a 2002 American Heart Association scientific statement, the omega-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were recommended (at a dose of 2-4 g/d) for reducing triglycerides in patients with elevated triglycerides...
August 19, 2019: Circulation
Andrew P DeFilippis, Andrew R Chapman, Nicholas L Mills, James A de Lemos, Armin Arbab-Zadeh, L Kristin Newby, David A Morrow
While coronary thrombus overlying a disrupted atherosclerotic plaque has long been considered the hallmark and the primary therapeutic target for acute myocardial infarction (MI), multiple other mechanisms are now known to cause or contribute to MI. It is further recognized that a myocardial infarction (MI) is just one of many types of acute myocardial injury. The Fourth Universal Definition of Myocardial Infarction (UDMI) provides a taxonomy for acute myocardial injury, including five subtypes of MI and non-ischemic myocardial injury...
August 16, 2019: Circulation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"